

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/005263

International filing date: 15 December 2004 (15.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0329851.0
Filing date: 23 December 2003 (23.12.2003)

Date of receipt at the International Bureau: 09 February 2005 (09.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



PCT/GB 2004 / 0 0 5 2 6

10 JANUARY 2005



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely affects the company to certain additional company law rules.



Signed

Dated 17 December 2004


2000 04 21 00



1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

AFB/JAS/P9566GB

24DEC03 EB61828-2 D00571

2. Patent application number

(The Patent Office will fill this part in)

0329851.0

F01/7700 0.00-0329851.0 CHERNE

23 DEC 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

TEMREL INC.
9 Myrtle Street
Douglas
Isle of Man IM1 1ED

Patents ADP number (if you know it)

8778557001

If the applicant is a corporate body, give the country/state of its incorporation

British Virgin Islands

4. Title of the invention

PROCESS FOR PRODUCING PARTICLES FOR
PHARMACEUTICAL COMPOSITIONS

5. Name of your agent (if you have one)

W. H. Beck, Greener & Co.

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

W. H. Beck, Greener & Co.
7 Stone Buildings
Lincoln's Inn
London WC2A 3SZ

Beck Greener
Fulwood House
12 ~~the~~ Fulwood Place
London

Patents ADP number (if you know it)

323001 - 0899 1754001 WCLV 6 HR

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note d)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Yes


Otherwise answer NO (See note d)

Global
Pm
6/12/4.

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description	13
Claim(s)	6
Abstract	1
Drawing(s)	3 + M 

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)


Request for a preliminary examination and search (Patents Form 9/77)

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)



Date 23.12.03

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Dr. James Stones - (020) 7693 5600

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Process for Producing Particles for Pharmaceutical Compositions

The present invention relates to a process to produce particles, particularly for use in pharmaceutical compositions. In particular, the invention relates to the use of water to control particle size.

US-A-5834021 (Speirs; published on 10th November 1998) discloses a non-disintegratable solid enteric composition comprising 5 wt % prednisolone metasulphobenzoate ("Pred-MSB") in an excipient matrix comprising 40 wt % microcrystalline cellulose, 35 wt % lactose and 20 wt % croscarmellose sodium. The composition is in the form of pellets having a diameter in the range of 1000 to 1400 μ m. The pellets are formed by dry mixing the Pred-MSB with the cellulose, the lactose and the croscarmellose sodium. Water is added to the mixture which is then stirred for 10 minutes to form an extrudable paste. The paste is extruded from a 25 mm diameter bowl through a 1 mm diameter tube of about 5 mm length at a rate of about 100 mm/min and spheronised on an 8 in (20 cm) plate rotated at about 1000 rpm for 10 to 15 minutes to provide said pellets. The resultant pellets are dried at 50°C for 30 min on a fluidised bed. The pellets are then coated with an Eudragit™ S100 (available from Röhm Pharma GmbH, Darmstadt, Germany) coating to provide a theoretical weight gain on coating of 11.6% and filled (15.7 mg per capsule) into size 1 hard gelatin capsules. The filled capsules are coated with an Eudragit™ L100 (also available from Röhm Pharma GmbH) coating to provide a theoretical weight gain on coating of 10.2%. The coated capsules may be used as a delayed and sustained release oral treatment of inflammatory bowel disease ("IBD").

Similar treatments of IBD are described in UK patent application Nos. 0215656.0 and 0215657.8 (Speirs; unpublished). The contents of US-A-5834021, GB0215656.0 and GB0215657.8 are incorporated herein by reference.

The diameter of the pellets is usually in the range between from about 500 to 2500 μm , preferably 800 to 1700 μm , more preferably 800 to 1500 μm and still more preferably 1000 to 1500 μm . However, it should be appreciated that pellets may have a diameter anywhere within the
5 aforementioned ranges and that a capsule may have pellets having a range of diameters. One reason pellets of this size are preferred is that they may be coated satisfactorily with, for example, an enteric coating. Such enterically-coated pellets display the required release profile in the intestines. Smaller pellets tend to be less spherical and more elongated
10 and may be below the required size to allow homogeneous filling of capsules while retaining a sufficient number to distribute through the bowel. The preferred size ranges have been justified by bioscintigraphy, the results of which showing that 200 or so pellets obtained an appropriate spread throughout the bowel.

15

The process disclosed in US-A-5834021 produces a range of pellet sizes. The pellets have to be screened so that the pellets of required size can be collected. Pellets that are either too large or too small to be used effectively in the delayed and sustained release capsules would normally
20 be discarded resulting in significant wastage. Such wastage is obviously undesirable. There is a need therefore for an improved process that produces particles having a more favourable distribution of particle sizes that is more particles within the required diameter range, resulting in a reduction in the amount of wastage.

25

The inventors have discovered that even small variations, e.g. ± 5 wt %, in the amount of water used in the above-mentioned process causes a significant change in the size of the particles and the distribution of particle sizes. With this in mind, the inventors reasoned that particle size
30 and, more importantly, particle size distribution is dependant on the amount of water used. The inventors realised that the amount of water could, therefore, be used to control the particle size and distribution. In

this way, particles having different ranges of sizes could be produced.

According to a first aspect of the present invention, there is provided use of water to control particle size in a process comprising:

- 5 mixing water with a component composition comprising at least a rheology modifying agent to produce a paste;
- extruding at least a portion of the paste to form extrudate;
- spheronising at least a portion of the extrudate to form spheronised particles; and
- 10 drying at least a portion of the spheronised particles,

The term "paste" is intended to include wet granulate.

- 15 The particles of the present invention are typically pellets or granules. In preferred embodiments, the composition further comprises sugar and cellulose.

- 20 Without wishing to be bound by any particular theory, the amount of water affects particle size due to the state of hydration of the matrix of the particle. Once the amount of water passes a certain point, the matrix is too wet and forms large agglomerates. It would appear that a large amount of water is taken up by the rheology modifying agent. Beyond the saturation point for this process, the amount of water appears critical.

- 25 One advantage of the present invention is that more particles having a diameter within the required range, usually 800 to 1500 μm , are produced. Different pluralities of preferred pellets of this size may be treated/coated using different modalities or thicknesses of delayed release coating material in order to achieve release at specified areas of the bowel.
- 30 An example of such coated pluralities of pellets is disclosed in PCT/GB03/02911, the disclosure of which is incorporated herein by reference.

Such coated pluralities of pellets allow a number of clinical objectives to be met. For example, they allow continuous delivery of a drug to treat large areas of bowel where the drug would otherwise be absorbed or metabolised if suddenly released. In addition, they allow continuous delivery of a drug over a section of the bowel to increase contact with the absorptive mucosa thereby allowing maximum absorption whereas the drug would be broken down if otherwise released in one section. Further, where a drug at high concentration would be toxic to the gut mucosa, the pellets allow the drug to be continually available at low concentration thereby allowing absorption without or with reduced toxicity.

Water is usually used in an amount of between from about 180 wt % to about 190 wt % of the component composition and is preferably used in an amount of about 185 wt % of the component composition. The inventors found the amount of water used in the process to form the matrix by absorption to be surprisingly large. This large amount of water distinguishes the present invention over all other pelleting processes of which the inventors are aware.

Usually from about 80 % to about 98 % of particles and, typically between from about 90 % to 98 % of particles, have a diameter between the range of about 800 to about 1500 microns. Even though the number of particles whose diameter is within the required range is greater than for the process disclosed in US-A-5834021, the dry particles may be screened to obtain particles having a diameter with the range of about 800 to about 1500 μm and to remove particles whose diameter does not fall within that range.

Use of about 5 wt % less water usually reduces particle size significantly. Conversely, use of 5 wt % more water increases particle size

such that 100% of particles have a diameter greater than 1500 μm which is useless if the pellets are to be enterically coated and used to release an active into the bowels.

5 The use of less water reduces the particle size distribution such that fewer particles have a diameter within the desired 800 to 1500 μm range and the mean particle size is reduced. The use of more water increases particle size distribution until all pellets are greater than 1500 μm . Thus, preferred embodiments of the present invention increase the
10 number of useful particles and reduces the amount of waste.

Pellets produced according to the invention are particularly applicable to the delivery of high molecular weight compounds in which the integrity of the tertiary structure is critical to the efficacy and safety of
15 the compound. A particular advantage of these pellets is that an oral pharmaceutical composition may be prepared under gentle conditions relative to most pharmaceutical processes, whilst providing a desired release profile of the compound in the intestinal tract.

20 An example of a high molecular weight compound, which would benefit from formulation in a composition of the present invention is erythropoietin, a glycosylated protein hormone and haematopoietic growth factor, which is considered useful in the management of anaemia in chronic renal failure among other conditions and has been investigated in
25 the treatment of anaemia of inflammatory bowel disease as well as other normocytic-normochromic anaemias. Erythropoietin is conventionally administered subcutaneously or intravenously, although a tableted form of erythropoietin has been disclosed (RU-A-2152206).

30 Other classes of high molecular weight compound which may benefit from the present invention include interferons, TNF antagonists and specific protein and polypeptide agonists and antagonists of the

immune system, hormones, such as human growth hormone and cytokines and cytokine antagonists. Other high molecular weight compounds that might be used include vaccines.

5 Particles produced according to the invention are also particularly useful in the delivery of anti-infective compounds such as metronidazole. Such pellets achieve high concentrations of the anti-infective compounds in the lumen of the gut and at the gut wall and allow the anti-infective agent to be disseminated through an appropriate extended area of the
10 gut. In addition, pellets comprising an anti-inflammatory agent also achieve a high concentration of the agent in the gut wall.

Other compounds and classes of compound whose administration may benefit from the present invention include analgesics and
15 antipyretics; antibacterial and antiprotozoal agents, such as metronidazole, albendazole, mebendazole, praziquantel and other nitroimidazole antibiotics and antibiotics active against anaerobic bacteria; clarithromycin and other macrolide antibiotics; gentamycin, ciprofloxacin, rifabutin and other such antibiotics active against infective
20 organisms commonly associated with or causing disorders of the intestine; antiinflammatory agents such as, salicylates, for example 5-aminosalicylic acid, 4-aminosalicylic acid and derivatives, such as balsalazide, steroids, especially prednisolone metasulphobenzoate; probiotics and prebiotics which have been shown to influence the
25 symptoms of inflammatory bowel disease and irritable bowel syndrome and recovery from antibiotic-associated diarrhea. Similarly, pharmacologically active drug substances known to influence the symptoms of irritable bowel syndrome, particularly by affecting neurotransmission in the gut at local sites such as those affecting the
30 serotonergic system and those active at the site of opiate receptors. α -amylase and paracetamol may also be administered using the composition of the present invention.

Other compounds which may benefit from the present invention include certain compounds that have toxic effects which limit their clinical usefulness, especially by causing local toxicity in specific areas of the gastrointestinal tract. Included among such compounds are examples of antibiotics, bisphosphonates and antiinflammatory drugs. A particular example is metformin, which is intolerable to many patients due to adverse effects on the gastrointestinal tract. The present invention may be utilised to minimise the concentration of the compound at the specific sites of toxicity and so allowing an effective therapeutic dose to be administered with a reduction in adverse events.

Pharmacologically acceptable salts and derivatives of the active compounds may also be used.

The preferred compounds for use in the present invention are prednisolone sodium metasulphobenzoate, 5-aminosalicylic acid, metronidazole, clarithromycin, metformin, paracetamol, α -amylase and erythropoietin. In the case of prednisolone pellets, the particles may be used to treat inflammatory bowel disease, for example, in a delayed and sustained release oral medicament.

The therapeutically active compound is preferably present in a therapeutically effective amount, usually between from more than 0 wt % to about 90 wt%, preferably between from more than 0 wt % to 40 wt %, of the component composition. The final amount of the active depends on the potency of the active. Therefore, actives that have relatively higher potency, for example erythropoietin, may be present in an amount between from more than 0 wt % to about 1 wt %. In addition, actives that have relatively lower potency, for example prednisolone or metronidazole, may be present in an amount between from about 5 wt % to about 20 wt %.

One preferred composition consists essentially of prednisolone or a pharmacologically acceptable salt (e.g. prednisolone sodium metasulphobenzoate) or derivative thereof, rheology modifying agent,
5 sugar and cellulose.

A second preferred composition consists essentially of metronidazole or a pharmacologically acceptable salt or derivative thereof, rheology modifying agent, sugar and cellulose.

10

A third preferred composition consists essentially of erythropoietin or a pharmacologically acceptable salt or derivative thereof, rheology modifying agent, sugar and cellulose.

15

The rheology modifying agent swells upon hydration to form a gel-like matrix having visco-elastic properties. A preferred rheology modifying agent is croscarmellose sodium, e.g. Ac-Di-Sol™ (FMC Biopolymer, 1735 Market Street, Philadelphia, PA 19103, USA). Croscarmellose sodium is usually used as a super disintegrant, i.e. a compound that assists
20 dissolution of a composition. It is, therefore, surprising and totally unexpected that a super disintegrant would form a gel-like matrix. The rheology modifying agent is present in an amount of at least 5 wt % of the component composition, preferably at least 10 wt % and more preferably in an amount of between from about 10 to about 40 wt %, e.g. 20 wt %, of
25 the component composition.

The sugar is preferably lactose monohydrate. The sugar is preferably present in an amount of between from about 30 to about 50 wt %, e.g. 35 wt %, of the component composition.

30

The cellulose is preferably microcrystalline cellulose. The cellulose is preferably present in an amount of between from about 35 to about 45

wt %, e.g. 30 wt %, of the component composition.

The speed of the spheroniser is very slow in comparison to that in known pellet manufacturing processes. For the purposes of the present invention, the spheronising plate usually rotates at between from about 125 rpm to 1800 rpm, preferably 200 rpm to 1000 rpm and, if the speed of rotation used is outside this range then the spheroniser usually fails to make pellets. In addition, with knowledge of known processes, the use of a smaller spheronising plate would intuitively require a faster rotation speed. However, in the present invention, the reverse is true and a smaller plate requires a faster speed of rotation. To the inventors' knowledge, this observation is unique in pellet manufacturing.

Controlling the amount of water used allows optimisation of the size distribution of particles at maximum process yields. The particles are intended for a particular purpose, for example medical treatment of a condition, e.g. IBD.

The resultant particles may be coated with an enteric coating such as Eudragit™ S which is an anionic copolymer of methacrylic acid and methacrylic acid methyl ester in which the ratio of free carboxylic groups to ester groups is approximately 1 : 2 and has a mean molecular weight of 135,000. A plurality of the coated particles may be encapsulated in a capsule or compressed into a tablet. The capsule or tablet may be coated with another enteric coating such as Eudragit™ L which differs from Eudragit S in that the ratio of free carboxylic groups to ester groups is approximately 1 : 1. Both Eudragit™ L and Eudragit™ S are insoluble in gastric juice (about pH 6) but only Eudragit™ L is readily soluble in intestinal juice below about pH 7. In this way, release of the active component is delayed until the colon and sustained to increase the effectiveness of the active. Sustained release is believed to be achieved at least in part through the coating becoming permeable.

It is believed currently that the gel-like matrix is formed from the cellulosic components of the pellets upon rehydration. In preferred embodiments, the cellulosic components are microcrystalline cellulose and croscarmellose sodium (a cellulose derivative). On rehydration, the pellets swell and release the active component in a sustained manner over time. The pellets also become "sticky" on rehydration and stick to the gut wall. As a result, the swollen pellets stick to the target site in the gut thereby increasing the effectiveness of the active. In addition, the pH within the gut increases from the centre of the gut lumen to the wall of the gut. Where the pellets are coated with a pH dependent release coating material, the rate of release of the active increases as the pellets approach the gut wall. This feature of preferred embodiments of the invention may also increase the effectiveness of the active.

The results also indicate that the overall yield (after drying) of the particles increases as the amount of water used approaches the optimum amount.

In a second aspect of the present invention, there is provided a process for the production of particles for use in a pharmaceutical composition, said process comprising the steps of:

- mixing water with a component composition comprising at least a rheology modifying agent to produce a paste;
- extruding at least a portion of the paste to form extrudate;
- spheronising at least a portion of the extrudate to form spheronised particles; and
- drying at least a portion of the spheronised particles.

Preferably, the amount of water used is between from about 180 to about 190 wt % of the weight of the component composition and, where the spheronising step uses a rotation 70 cm plate, the plate does not

rotate at about 33 rpm.

The process of the second aspect may have any or all of the preferred features of the process defined above, in any appropriate
5 combination.

Preferred embodiments of the present invention will now be described, by way of example only and with reference to the accompanying figures. In the figures:

10 Figure 1 is a photograph of uncoated pellets produced in Example 1;

Figure 2 is a photograph of uncoated pellets produced in Example 2; and

15 Figure 3 is a photograph of uncoated pellets produced in Example 3.

Example 1

Prednisolone metasulphobenzoate pellets were prepared by
20 preparing a dry mix of 5 wt% prednisolone sodium metasulphobenzoate, 40 wt% microcrystalline cellulose (Avicel™ PH 101), 35 wt% lactose monohydrate (D80 200 Mesh) and 20 wt% croscarmellose sodium (Ac-Di-Sol™). Purified water (185 wt% of the dry mix components) was added and the resulting mixture mixed for 10 minutes to form and extrudable
25 paste which was then extruded and spheronised. The pellets were then dried in a fluid bed granulator and screened to ensure the size of the particles was in the range 800 to 1500 µm.

Figure 1 depicts the pellets formed by Example 1. The majority of
30 these pellets are within the required range of 800 to 1500 µm.

Example 2

Pellets were formed using the steps described in Example 1 although only 180 wt % water was used instead of 185 wt %. The yield
5 (after drying) of the pellets was 91 %.

Figure 2 depicts the pellets formed by Example 2. The photograph clearly shows that the size of the pellets is reduced significantly when less water is used.

10

Example 3

Pellets were formed using the steps described in Example 1 although 190 wt % water was used instead of 185 wt %.

15

Figure 3 depicts the pellets formed by Example 3. The photograph clearly shows that the size of the pellets is increased significantly when more water is used.

20 Example 4

Pellets were formed using the steps described in Example 1 although only 182.5 wt % water was used instead of 185 wt %. The yield (after drying) of the pellets was 96.5 %.

25

Example 5

Pellets were formed using the steps described in Example 1 although only 177.5 wt % water was used instead of 185 wt %. The yield
30 (after drying) of the pellets was 85 %.

It will be appreciated that the invention is not restricted to the

details described above with reference to the preferred embodiments but that numerous modifications and variations can be made without departing from the spirit or scope of the invention as defined by the following claims.

CLAIMS

1. Use of water to control particle size in a process comprising:
mixing water with a component composition comprising at least a
5 rheology modifying agent to produce a paste;
extruding at least a portion of the paste to form extrudate;
spheronising at least a portion of the extrudate to form spheronised
particles; and
drying at least a portion of the spheronised particles.
10
2. Use as claimed in Claim 1 wherein water is used in an amount of
between from about 180 wt % to about 190 wt % of the component
composition.
- 15 3. Use as claimed in Claim 1 or Claim 2 wherein water is used in an
amount of about 185 wt % of the component composition.
4. Use as claimed in any of Claims 1 to 3 wherein between from about
80 % to about 98 % of particles have a diameter between the range of
20 about 800 to about 1500 μm .
5. Use as claimed in any of the preceding claims wherein between from
about 95 % to about 98 % of particles have a diameter between the range
of about 800 to about 1500 μm .
25
6. Use as claimed in Claim 3 wherein use of 5 wt % more water
increases particle size such that substantially all of the particles have a
diameter over 1500 μm .
- 30 7. Use as claimed in any of the preceding claims wherein the dry
particles are screened to obtain particles having a diameter with the range
of about 800 to about 1500 μm .

8. Use as claimed in any of the preceding claims wherein the composition further comprises a therapeutically active compound selected from interferons, TNF antagonists, protein and peptide agonists and
5 antagonists of the immune system, hormones, cytokines and cytokine agonists, analgesics, antipyretics, antibacterial and antiprotozoal agents, anti-infective agents, antibiotics, antiviral agents, antimalarial agents, anti-inflammatory agents, steroids, probiotics and prebiotics, opiate agonists and antagonists and pharmacologically acceptable salts and
10 derivatives of each of these actives.

9. Use as claimed in any of the preceding claims wherein the composition further comprises a therapeutically active compound selected from erythropoietin, human growth hormone, metronidazole, albendazole,
15 mebendazole, praziquantel, clarithromycin, gentamycin, ciprofloxacin, rifabutin, 5-aminosalicylic acid, 4-aminosalicylic acid, balsalazide, prednisolone, α -amylase and paracetamol or pharmacologically acceptable salts or derivatives thereof.

20 10. Use as claimed in Claim 9 or Claim 10 wherein the therapeutically active compound is prednisolone or a pharmacologically acceptable salt or derivative thereof.

11. Use as claimed in Claim 9 or Claim 10 wherein the therapeutically
25 active compound is metronidazole or a pharmacologically acceptable salt or derivative thereof.

12. Use as claimed in Claim 9 or Claim 10 wherein the therapeutically active compound is erythropoietin or a pharmacologically acceptable salt
30 or derivative thereof.

13. Use as claimed in any of Claims 8 to 12 wherein the therapeutically

active compound is present in the composition in a therapeutic amount.

14. Use as claimed in any of Claim 8 to 13 wherein the therapeutically active compound is present in an amount between from more than 0 wt %
5 to about 90 wt% of the component composition.

15. Use as claimed in any of Claim 8 to 14 wherein the therapeutically active compound is present in an amount between from more than 0 wt %
to about 40 wt% of the component composition.

10

16. Use as claimed in any of Claim 8 to 15 wherein the therapeutically active compound is present in an amount between from about 5 wt % to
about 20 wt% of the component composition.

15 17. Use as claimed in any of Claim 8 to 15 wherein the therapeutically active compound is present in an amount between from more than 0 wt %
to about 1 wt % of the component composition.

18. Use as claimed in any of the preceding claims wherein the rheology
20 modifying agent comprises croscarmellose sodium.

19. Use as claimed in any of the preceding claims wherein the rheology modifying agent is Ac-Di-Sol™.

25 20. Use as claimed in any of the preceding claims wherein the rheology modifying agent is present in an amount of at least 5 wt % of the
component composition.

21. Use as claimed in any of the preceding claims wherein the rheology
30 modifying agent is present in an amount of at least 10 wt % of the
component composition.

22. Use as claimed in any of the preceding claims wherein the rheology modifying agent is present in an amount of between from about 10 to about 40 wt % of the component composition.

5 23. Use as claimed in any of the preceding claims wherein the rheology modifying agent is present in an amount of about 20 wt % of the component composition.

10 24. Use as claimed in any of the preceding claims wherein the component composition further comprises sugar.

25. Use as claimed in Claim 24 wherein the sugar is lactose monohydrate.

15 26. Use as claimed in Claim 24 or Claim 25 wherein the sugar is present in an amount of between from about 30 to about 50 wt % of the component composition.

20 27. Use as claimed in any of Claims 24 to 26 wherein the sugar is present in an amount of about 35 wt % of the component composition.

28. Use as claimed in any of the preceding claims wherein the component composition further comprises cellulose.

25 29. Use as claimed in Claim 28 wherein the cellulose is microcrystalline cellulose.

30 30. Use as claimed in Claim 28 or Claim 29 wherein the cellulose is present in an amount of between from about 35 to about 45 wt % of the component composition.

31. Use as claimed in any of Claims 28 to 30 wherein the cellulose is

present in an amount of about 30 wt % of the component composition.

32. Use as claimed in any of the preceding claims wherein the composition consists essentially of prednisolone or a pharmacologically acceptable salt or derivative thereof, a rheology modifying agent, sugar and cellulose.

33. Use as claimed in any of Claims 1 to 31 wherein the composition consists essentially of metronidazole or a pharmacologically acceptable salt or derivative thereof, a rheology modifying agent, sugar and cellulose.

34. Use as claimed in any of Claims 1 to 31 wherein the composition consists essentially of erythropoetin or a pharmacologically acceptable salt or derivative thereof, a rheology modifying agent, sugar and cellulose.

35. Use substantially as hereinbefore described with reference to the accompanying examples.

36. A process for the production of particles for use in a pharmaceutical composition, said process comprising the steps of:

mixing water with a component composition comprising at least a rheology modifying agent to produce a paste;

extruding at least a portion of the paste to form extrudate;

spheronising at least a portion of the extrudate to form spheronised particles; and

drying at least a portion of the spheronised particles.

37. A process as claimed in Claim 36 wherein the amount of water used is between from about 180 to about 190 wt % of the weight of the component composition and, where the spheronising step uses a rotation 70 cm plate, the plate does not rotate at about 33 rpm.


38. A process as claimed in Claim 36 or Claim 37 wherein the process comprises any of the features defined in Claims 2 to 35.

39. A process substantially as hereinbefore described with reference to
5 the accompanying examples.

ABSTRACT

Process for Producing Particles for Pharmaceutical Compositions

5 Water is used to control particle size in a process comprising mixing
water with a composition comprising a rheology modifying agent and
possibly sugar and cellulose to produce a paste. The paste is extruded to
form particles which are then spheronised and dried. One advantage of
using water to control particle size is that the number of particles having
10 a diameter within a required range, e.g. between from about 800 to about
1500 μm , may be increased.



5

FIGURE 1



2 / 3





FIGURE 2





5

FIGURE 3

